Marwan Masri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Marwan Masri has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
A. Barbari
2 shared publicationsA. Stephan
2 shared publicationsM. Rost
2 shared publicationsS. Rizk
2 shared publicationsA Barbari
Transplant Unit, Rizk Hospital, Beirut, Lebanon
1 shared publicationA Stephan
Transplant Unit, Rizk Hospital, Beirut, Lebanon
1 shared publication
Latest Publications
- 1 May 2007
- Published by Elsevier in Transplantation Proceedings
- Vol. 39 (4) , 1204-1206
An Assay for the Determination of Sirolimus Levels in the Lymphocyte of Transplant Patients
- 1 May 2007
- Published by Elsevier in Transplantation Proceedings
- Vol. 39 (4) , 1204-1206
An Assay for the Determination of Sirolimus Levels in the Lymphocyte of Transplant Patients
- 1 September 2005
- Published by Elsevier in Transplantation Proceedings
- Vol. 37 (7) , 2988-2993
Switchability of Neoral and Equoral According to Food and Drug Administration Rules and Regulations
- 1 September 2005
- Published by Elsevier in Transplantation Proceedings
- Vol. 37 (7) , 2988-2993
Switchability of Neoral and Equoral According to Food and Drug Administration Rules and Regulations
- 1 December 2004
- Vol. 2 (2) , 217-20
Middle East Society for Organ Transplantation (MESOT) Transplant Registry.
During the seventies, sporadic renal transplants were performed in few MESOT-region countries, mainly Turkey, Iran, Egypt, and Lebanon. Since the introduction of cyclosporine in the early eighties, transplantation has become the preferred therapeutic modality for end-stage renal failure. In 1986, the Islamic theologians (Al Aloma) issued what became known as the Amman declaration, in which they accepted brain death and retrieval and transplantation of organs from living and cadaveric donors. Based on this and similar declarations, all Middle Eastern countries except Egypt passed laws that allow cadaveric transplantation and regulate live donations. Iran, Turkey, Saudi Arabia, Kuwait, Tunisia, Jordan, and Lebanon all have current active cadaveric programs and perform liver, heart, pancreas, and lung transplants. More than 5088 renal transplants/year are performed in the region with Iran leading with 1600. The cumulative number of renal transplant patients is now nearly 60,000. With a 2003 population of 600,682,175, the rate/million for renal transplantation in the MESOT region is a mere 9/million. Rates of renal transplantation range from 31/million in some countries to 0 in others. The major obstacle in establishing an accurate number of transplants is "tourist transplantation," in which the same transplanted patients are registered in different countries. Although cadaveric programs have been active for more than 10 years, live-related and nonrelated transplants account for nearly 85% of the total transplants. The data presented were collected from MESOT representatives in the region and from publications. For proper compilation of the registry, a format is being proposed that will be presented at the Congress for review and adaptation. Even with the limited resources in the region, immunosuppressive drugs for induction and maintenance therapy are available and are used. Costs for transplantation and immunosuppressive therapy are either totally or heavily supported by governmental agencies.
- 1 December 2004
- Vol. 2 (2) , 217-20
Middle East Society for Organ Transplantation (MESOT) Transplant Registry.
During the seventies, sporadic renal transplants were performed in few MESOT-region countries, mainly Turkey, Iran, Egypt, and Lebanon. Since the introduction of cyclosporine in the early eighties, transplantation has become the preferred therapeutic modality for end-stage renal failure. In 1986, the Islamic theologians (Al Aloma) issued what became known as the Amman declaration, in which they accepted brain death and retrieval and transplantation of organs from living and cadaveric donors. Based on this and similar declarations, all Middle Eastern countries except Egypt passed laws that allow cadaveric transplantation and regulate live donations. Iran, Turkey, Saudi Arabia, Kuwait, Tunisia, Jordan, and Lebanon all have current active cadaveric programs and perform liver, heart, pancreas, and lung transplants. More than 5088 renal transplants/year are performed in the region with Iran leading with 1600. The cumulative number of renal transplant patients is now nearly 60,000. With a 2003 population of 600,682,175, the rate/million for renal transplantation in the MESOT region is a mere 9/million. Rates of renal transplantation range from 31/million in some countries to 0 in others. The major obstacle in establishing an accurate number of transplants is "tourist transplantation," in which the same transplanted patients are registered in different countries. Although cadaveric programs have been active for more than 10 years, live-related and nonrelated transplants account for nearly 85% of the total transplants. The data presented were collected from MESOT representatives in the region and from publications. For proper compilation of the registry, a format is being proposed that will be presented at the Congress for review and adaptation. Even with the limited resources in the region, immunosuppressive drugs for induction and maintenance therapy are available and are used. Costs for transplantation and immunosuppressive therapy are either totally or heavily supported by governmental agencies.
- 1 December 2003
- Vol. 1 (2) , 119-24
Bioavailability versus bioequivalence: the cyclosporine model.
The quest for a fixed-dose immunosuppressive drug continues. Experience with cyclosporine, tacrolimus and mycophenolate mofetil has taught us that there is no correlation between dose and clinical events. These data indicate that the concentration of the drug at the site of action (bioavailability) of each of these agents differs from one patient to the next. In addition, the bioequivalence (concentration of intact drug at the site of action resulting in a measurable response [effect]) may differ among individuals. Technically, it is very difficult to measure the drug concentration at a particular site, especially in organs or tissues that are not directly accessible. Therapeutic drug-blood-level monitoring is a simple indirect method that is used to estimate both bioavailability and bioequivalence. However, the immunosuppressive effect of all these drugs is initiated by binding to receptors on the surface of lymphocytes, which leads to inhibition of cytokine production and proliferation of activated lymphocytes. Thus, it would be more advantageous to monitor the level and effect of these drugs at the site of action (bioequivalence), the lymphocyte. This report describes an assay of this type that was developed for monitoring transplant patients at one center. The assay is based on measuring drug levels in the cytoplasm of lymphocytes. It is quick and easy to perform (20 samples per hour), inexpensive, and reproducible. The between-run Coefficient of Variance (CV) is 5.4 and a within-run CV is 3.1. For this study, blood and lymphocyte drug levels in transplant patients were determined and correlated with graft function and clinical events (biopsy-proven rejection and/ or toxicity).
- 1 December 2003
- Vol. 1 (2) , 119-24
Bioavailability versus bioequivalence: the cyclosporine model.
The quest for a fixed-dose immunosuppressive drug continues. Experience with cyclosporine, tacrolimus and mycophenolate mofetil has taught us that there is no correlation between dose and clinical events. These data indicate that the concentration of the drug at the site of action (bioavailability) of each of these agents differs from one patient to the next. In addition, the bioequivalence (concentration of intact drug at the site of action resulting in a measurable response [effect]) may differ among individuals. Technically, it is very difficult to measure the drug concentration at a particular site, especially in organs or tissues that are not directly accessible. Therapeutic drug-blood-level monitoring is a simple indirect method that is used to estimate both bioavailability and bioequivalence. However, the immunosuppressive effect of all these drugs is initiated by binding to receptors on the surface of lymphocytes, which leads to inhibition of cytokine production and proliferation of activated lymphocytes. Thus, it would be more advantageous to monitor the level and effect of these drugs at the site of action (bioequivalence), the lymphocyte. This report describes an assay of this type that was developed for monitoring transplant patients at one center. The assay is based on measuring drug levels in the cytoplasm of lymphocytes. It is quick and easy to perform (20 samples per hour), inexpensive, and reproducible. The between-run Coefficient of Variance (CV) is 5.4 and a within-run CV is 3.1. For this study, blood and lymphocyte drug levels in transplant patients were determined and correlated with graft function and clinical events (biopsy-proven rejection and/ or toxicity).
- 5 November 2003
- Published by Elsevier in Transplantation Proceedings
- Vol. 35 (7) , 2745-2747
The role of generics in transplantation
- 5 November 2003
- Published by Elsevier in Transplantation Proceedings
- Vol. 35 (7) , 2745-2747
The role of generics in transplantation
- 5 November 2003
- Published by Elsevier in Transplantation Proceedings
- Vol. 35 (7) , 2755-2756
Technical limitations of immunosuppressive drug therapy blood level monitoring
- 5 November 2003
- Published by Elsevier in Transplantation Proceedings
- Vol. 35 (7) , 2755-2756
Technical limitations of immunosuppressive drug therapy blood level monitoring
- 1 July 2003
- Published by Elsevier in Molecular Immunology
- Vol. 39 (17-18) , 1073-1077
The mosaic of immunosuppressive drugs
- 1 July 2003
- Published by Elsevier in Molecular Immunology
- Vol. 39 (17-18) , 1073-1077
The mosaic of immunosuppressive drugs
- 1 July 2003
- Published by Elsevier in Molecular Immunology
- Vol. 39 (17-18) , 1057
Editorial
- 23 June 2003
- Published by Elsevier in Molecular Immunology
- Vol. 39 (17-18) , 1059-1060
Cyclosporine blood level monitoringCross-reactivity of anti-Cyclosporine A monoclonal with its sulphate metabolite: an in vitro study
- 23 June 2003
- Published by Elsevier in Molecular Immunology
- Vol. 39 (17-18) , 1059-1060
Cyclosporine blood level monitoringCross-reactivity of anti-Cyclosporine A monoclonal with its sulphate metabolite: an in vitro study